Pharma BD Deal Intelligence
Gilead / CV Therapeutics: Partially Achieved (Score: 64/100)
Full analysis, sources & comparables →Gilead acquired CV Therapeutics for $1.4B for Ranexa and Lexiscan.
Gilead / CV Therapeutics: Partially Achieved (Score: 64/100)
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / CV Therapeutics Inc. (this deal) | 2009 | $1.4B | 62 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2009 deals · Gilead Sciences Inc. deals · Cardiovascular deals